Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Restructuring Costs (2022)

Corbus Pharmaceuticals Holdings has reported Restructuring Costs over the past 1 years, most recently at $5.0 million for Q2 2022.

  • For Q2 2022, Restructuring Costs changed N/A year-over-year to $5.0 million; the TTM value through Jun 2023 reached $5.0 million, changed N/A, while the annual FY2022 figure was $5.0 million, N/A changed from the prior year.
  • Restructuring Costs for Q2 2022 was $5.0 million at Corbus Pharmaceuticals Holdings.
  • Over five years, Restructuring Costs peaked at $5.0 million in Q2 2022 and troughed at $5.0 million in Q2 2022.